Table 2.
Drug | Solubility | pKa | log P | BCS classification | Half-life | % Bioavailability |
---|---|---|---|---|---|---|
Tenofovir | 13.4 mg/ml | 1.3; 7.9; 3.0; 5.3 | −1.1 | Class III | 17 | 25–39 |
Emtricitabine | 112 mg/ml | 2.63 | −0.43 | Class I | 10 | 93 |
Efavirenz | <10 μg/ml | 10.2 | 3.68 | Class II | 40–50 | 42–80 |
Nevirapine | 100 μg/ml | 2.8 | 2.05 | Class II | 25–30 | >90 |
Dapivirine | <10 μg/ml | 5.8 | 5.27 | Class II | N.A. | N.A. |
Etravirine | <10 μg/ml | 3.5 | 5.2 | Class IV | 30–40 | N.A. |
Rilpivirine | <10 μg/ml | 5.6 | 4.86 | Class II | 34–55 | 24 (monkeys) |
Raltegravir | <1 mg/ml | ∼1.25 | 1.06 | Class II | 9 | ∼65% |
Maraviroc | ∼1 mg/ml | 3.3, 7.9 | 4.37 | Class III | 14–18 | 23–33 |
N.A., not available.